5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol-triacetate-ester.
Resveratrol with its three phenol groups capped by acetate. Esterases in your gut, blood and liver strip the caps, so what ends up circulating is resveratrol itself.
- Category
- Compound
What 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol-triacetate-ester is, and what it does.
- Does it work
- Suits a formulator who wants resveratrol that holds up better on the shelf and past the first pass. If plain resveratrol already works for you, this is the same destination.
- How much to take
- No dose figure is on record for the ester. It weighs more than resveratrol by three acetate groups, so a given weight delivers a little less of the parent molecule.
- Time to feel it
- Nobody has published a human time course for the ester. The uncapping happens across the first hours after a dose, before anything else can follow.
- The first dose
- Day one is chemistry: carboxylesterases in the gut wall, plasma and liver cutting the acetate caps off. No sensation attaches to that step.
- With regular use
- Weeks of daily use put you where resveratrol research sits, since that is what the body ends up with. The ester's own long-term data has not been gathered.
- How well tolerated
- No standalone human safety dataset exists for the ester. Resveratrol is well tolerated at supplement amounts, and anyone on blood-thinning medication should ask a doctor.
- How it feels
- Nothing distinctive is described. Where this shows up is in blood levels of resveratrol and its conjugates, measured rather than felt.
- The overlooked benefit
- Capping the phenols also strips out the hydrogen-bond donors, which is why the powder handles light and oxygen better than free resveratrol on the same shelf.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Conversion to resveratrol by carboxylesterasesAnimal study
- Protection of phenolic groups from first-pass conjugationNarrative review
- Light and oxygen stability of the acetylated formIn vitro study
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
This compound is resveratrol with its phenolic hydroxyl groups capped as acetate esters. Carboxylesterases in the gut wall and liver cleave the acetates and release resveratrol itself, which is the species that does the downstream work. Any activity attributed to the ester is activity of the resveratrol it liberates. The two are not additive, they are the same molecule at different points in the same sequence.
Free resveratrol is cleared very quickly by sulfotransferases and UDP-glucuronosyltransferases in the intestinal wall, which is the main reason its plasma levels stay low. Quercetin is a substrate and inhibitor of the same enzymes and competes for them. The result is a measured change in resveratrol pharmacokinetics, which is not the same as a change in any outcome.
Piperine inhibits intestinal UDP-glucuronosyltransferase activity and slows first-pass conjugation of polyphenols. Acetylated stilbenes still face that conjugation once the esterases have freed the parent, so the pairing addresses a real bottleneck. Piperine inhibits drug-metabolising enzymes broadly, which is a reason to check anything else being taken.
Acetylation raises lipophilicity and lowers aqueous solubility further than the parent stilbene, so dissolution becomes the rate-limiting step. Phospholipid dispersion keeps the compound in a solubilised state through the gut. This addresses dissolution, not metabolism.
Phospholipid complexes are the standard formulation answer for poorly soluble polyphenols and give measurably higher plasma appearance. The acetylated stilbene is a good candidate because its solubility problem is worse than the parent's. Absorption is the endpoint being changed here.
A lipid vehicle promotes bile release and micelle formation, which is what a highly lipophilic acetylated stilbene needs to stay in solution through the small intestine. Taking it with a fat-containing meal does much the same. Dry powder taken on an empty stomach is the worst case for a compound like this.
Same reasoning as with other NAD precursors, the stilbene sits on the enzyme side and the precursor on the cosubstrate side. It is a coherent mechanistic story with thin human support. Read it as pathway logic rather than a demonstrated combination effect.
Pterostilbene is the dimethyl ether of resveratrol and resists phase II conjugation far better, so it persists longer in plasma. Combining it with an acetylated resveratrol prodrug gives two stilbenes with different clearance profiles. They also compete for the same conjugating enzymes, so the interaction runs in both directions.
Free stilbene phenols oxidise readily once the acetate caps are removed. Ascorbate in the same formulation lowers oxidative loss during storage and in the gut lumen. The benefit here is chemical stability rather than a physiological synergy.
Resveratrol inhibits platelet aggregation in laboratory systems, and long-chain omega-3 fatty acids do so through eicosanoid shifts. Stacking them at high intakes is worth flagging for anyone already on anticoagulant or antiplatelet medication. This is a caution rather than a benefit claim.
Nothing specific on file for 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol-triacetate-ester. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol-triacetate-ester actually does.
This is a modified form of resveratrol where its three active hydroxyl groups are capped, so it has no free active site and can't act as an antioxidant until those caps are removed in the body.
Enzymes in the gut wall, blood and liver remove those caps and release resveratrol, which makes this compound an inactive precursor rather than an active ingredient on its own.
The capping process removes certain reactive groups and makes the molecule more fat soluble, so this form is more stable to light and oxygen than plain resveratrol but dissolves less well in water.
Resveratrol and its modified forms exist as two different shapes around a central double bond, and UV light can flip one shape into the other, which is why these materials get stored and handled away from light.
Where 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol-triacetate-ester comes from.
Start with resveratrol, then chemically cap the three reactive spots on the molecule with acetate groups. That is the whole product. The caps come off in your gut and you end up with resveratrol, so this is a delivery trick rather than a different ingredient.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Sourced either from Japanese knotweed root extract, from yeast fermentation, or by chemical synthesis. The starting route is often not declared
Reaction with acetic anhydride in the presence of a base caps the three phenolic hydroxyl groups as acetate esters
The crystalline ester is recrystallised from solvent to remove partially acetylated intermediates and residual anhydride
Purity is set by chromatographic assay, with the trans to cis ratio and any residual free resveratrol both worth specifying
Filled directly, micronised, or dispersed into an oil or phospholipid carrier
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.